Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide) and GLP-2 analogs (e.g., teduglutide) are FDA-approved interventions that treat obesity and short bowel syndrome by mimicking enteroendocrine cell hormone secretion.
If you have obesity or short bowel syndrome, talk to your doctor about GLP-1 based medications like semaglutide. These are FDA-approved treatments that mimic your gut's natural hormones to help with weight loss or nutrient absorption. They are not lifestyle fixes but medical interventions for specific conditions.
StrongSupportsVERY_HIGH confidence
One formulation of semaglutide, Wegovy, has recently been FDA-approved for treating obesity in adults and children over 12 years of age [140].
Why this rating
The paper cites FDA approval and multiple clinical trials (Phase 2/3) for these specific drugs.
Source
Intestinal Enteroendocrine Cells: Present and Future Druggable Targets
Roger Atanga et al. · International Journal of Molecular Sciences · 2023
narrative_reviewCited 49×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →